Sales Highlights: Global FYTD Mar 2024 AUD$3.6M, up 154% on (prior comparative period) pcp. Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter. Australia: FYTD Mar 2024 AUD$2.8M, up 234% on pcp. Mar 2024 Quarter AUD$0.9M, up 66% on pcp and 99% on last quarter. USA: FYTD Mar 2024 AUD$0.8M, up 35% on pcp. Mar 2024 Quarter AUD$0.3M, up 7% on pcp and 18% on last quarter. Sales commenced on Walmart.com. Flavio Palumbo, Chief Commercial Officer said “We continue to be excited by the strong sales results on Travelan. Immuron’s investment to drive awareness of the Travelan brand has seen continued strong sales results in Australia. We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring (Mar-May) / summer (Jun-Aug) vacation peak period.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRN:
- Immuron Travelan® sales continued strong growth
- Immuron proceeding to Phase 3 trials for Travelan after positive results
- Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
- Immuron trading halted, news pending
- Immuron Presentation Australian Biologics Festival 2024
